TY - JOUR
T1 - Disparities in acute myeloid leukemia treatments and outcomes
AU - Eisfeld, Ann Kathrin
N1 - Publisher Copyright:
© 2024 Lippincott Williams and Wilkins. All rights reserved.
PY - 2024/3/1
Y1 - 2024/3/1
N2 - Purpose of reviewThis review aims to summarize different contributors to survival disparities in acute myeloid leukemia (AML) patients. The focus is set on African-American (hereafter referred to as Black) patients, with separate consideration of self-reported race and ancestry. It aims to also highlight the interconnectivity of the different features that impact on despair survival.Recent findingsThe main themes in the literature covered in this article include the impact of social deprivation, clinical trial enrollment and biobanking, structural racism and ancestry-associated differences in genetic features on survival outcomes.SummaryAn increasing number of studies have not only shown persistent survival disparities between Black and non-Hispanic White AML patients, but uncovered a multitude of contributors that have additive adverse effects on patient outcomes. In addition to potentially modifiable features, such as socioeconomic factors and trial enrollment odds that require urgent interventions, there is emerging data on differences in disease biology with respect to genetic ancestry, including frequencies of known AML-driver mutations and their associated prognostic impact.
AB - Purpose of reviewThis review aims to summarize different contributors to survival disparities in acute myeloid leukemia (AML) patients. The focus is set on African-American (hereafter referred to as Black) patients, with separate consideration of self-reported race and ancestry. It aims to also highlight the interconnectivity of the different features that impact on despair survival.Recent findingsThe main themes in the literature covered in this article include the impact of social deprivation, clinical trial enrollment and biobanking, structural racism and ancestry-associated differences in genetic features on survival outcomes.SummaryAn increasing number of studies have not only shown persistent survival disparities between Black and non-Hispanic White AML patients, but uncovered a multitude of contributors that have additive adverse effects on patient outcomes. In addition to potentially modifiable features, such as socioeconomic factors and trial enrollment odds that require urgent interventions, there is emerging data on differences in disease biology with respect to genetic ancestry, including frequencies of known AML-driver mutations and their associated prognostic impact.
KW - ancestry
KW - race
KW - socioeconomic features
KW - survival disparities
UR - http://www.scopus.com/inward/record.url?scp=85183944474&partnerID=8YFLogxK
U2 - 10.1097/MOH.0000000000000797
DO - 10.1097/MOH.0000000000000797
M3 - Review article
C2 - 38059809
AN - SCOPUS:85183944474
SN - 1065-6251
VL - 31
SP - 58
EP - 63
JO - Current Opinion in Hematology
JF - Current Opinion in Hematology
IS - 2
ER -